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Background: Heart failure with left ventricular (LV) hypertrophy is often associated with insulin resistance and
inflammation. Recent studies have shown that dipeptidyl peptidase 4 (DPP4) inhibitors improve glucose
metabolism and inflammatory status. We therefore evaluated whether vildagliptin, a DPP4 inhibitor, prevents LV
hypertrophy and improves diastolic function in isoproterenol-treated rats.
Methods: Male Wistar rats received vehicle (n = 20), subcutaneous isoproterenol (2.4 mg/kg/day, n = 20) (ISO),
subcutaneous isoproterenol (2.4 mg/kg/day + oral vildagliptin (30 mg/kg/day, n = 20) (ISO-VL), or vehicle + oral
vildagliptin (30 mg/kg/day, n = 20) (vehicle-VL) for 7 days.
Results: Blood pressure was similar among the four groups, whereas LV hypertrophy was significantly decreased
in the ISO-VL group compared with the ISO group (heart weight/body weight, vehicle: 3.2 ± 0.40, ISO: 4.43 ± 0.39,
ISO-VL: 4.14 ± 0.29, vehicle-VL: 3.16 ± 0.16, p < 0.05). Cardiac catheterization revealed that vildagliptin lowered the
elevated LV end-diastolic pressure observed in the ISO group, but other parameters regarding LV diastolic function
such as the decreased minimum dp/dt were not ameliorated in the ISO-VL group. Histological analysis showed that
vildagliptin attenuated the increased cardiomyocyte hypertrophy and perivascular fibrosis, but it did not affect
angiogenesis in cardiac tissue. In the ISO-VL group, quantitative PCR showed attenuation of increased mRNA expression
of tumor necrosis factor-α, interleukin-6, insulin-like growth factor-l, and restoration of decreased mRNA expression of
glucose transporter type 4.
Conclusions: Vildagliptin may prevent LV hypertrophy caused by continuous exposure to isoproterenol in rats.
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Heart failure with preserved ejection fraction (HFpEF) is
the most common form of heart failure in patients with
hypertension. HFpEF is associated with considerable
morbidity and mortality, and the risk of adverse out-
come increases with the severity of diastolic dysfunction
[1]. Treatment with anti-hypertensive drugs may be ef-
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stated.hypertensive drugs including angiotensin-converting
enzyme inhibitor and angiotensin receptor blocker have
failed to show a benefit to mortality or morbidity. Interest-
ingly, patients with HFpEF often have systemic insulin re-
sistance [2]. Recent studies have shown that systemic
insulin resistance contributes to dysregulated insulin and
metabolic signaling in the heart and the development of
diastolic dysfunction [3]. Furthermore, insulin resistance is
accompanied with chronic low-grade inflammation [4],
leading to the pathogenesis of hypertension and
chronic heart failure [5,6]. Accordingly, there has
been increased interest in restoring energy metabo-
lism and establishing anti-inflammatory therapies for
HFpEF.l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
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incretin hormone secreted mainly by the entero-endocrine
cells of the intestine in response to the presence of nutri-
ents [7]. GLP-1 receptors are expressed in rodent and hu-
man heart [8] and augment the intake of glucose to
myocytes to improve energy metabolism [9]. GLP-1 was
also reported to enhance L-type Ca2+ current in isolated
cardiomyocytes via activation of the cAMP-dependent
protein kinase A mechanism [10]. An experimental study
showed that a GLP-1 analog had protective effects on
high-fat diet–induced insulin resistance [11], inflamma-
tion [12], and myocardial infarction [13]. However, the
in vivo half-life of GLP-1 is very short (2 to 3 min) because
it is degraded by dipeptidyl peptidase 4 (DPP4), and thus
DPP4 inhibitors lead to increased GLP-1 levels in the
blood and extend the duration of GLP-1 action. Recent
experimental studies evaluated the protective effect of
DPP4 inhibitors in cardiovascular disease in hypertension
[14], heart failure [15], and myocardial infarction [16-18].
Recently, we reported that continuous infusion of
isoproterenol (ISO) induces cardiac hypertrophy and
diastolic dysfunction in rats [19]. Despite the above-
mentioned studies on cardiac function, the effects
of DPP4 inhibition on cardiac inflammation and car-
diac insulin resistance have not been fully elucidated.
Therefore, the purpose of this study was to investigate
whether a DPP4 inhibitor, vildagliptin, can prevent left
ventricular (LV) hypertrophy and LV diastolic function
in isoproterenol-treated rats.
Methods
Animals and drug infusion
Male Wistar rats weighing 193–222 g (8 weeks old; CLEA
Japan, Inc.) were used as described [19]. Delivery of iso-
proterenol or vehicle was achieved by subcutaneously im-
planting an osmotic minipump (Alzet, model 2001;
1.0 μL/h) in the neck under diethyl ether inhalation
anesthesia. Rats were divided into four groups and treated
for 7 days: vehicle group (subcutaneous pH 4.0 HCl in sa-
line, n = 10), ISO group (subcutaneous isoproterenol
2.4 mg/kg/day, n = 20), isoproterenol + vildagliptin group
(ISO-VL; subcutaneous isoproterenol 2.4 mg/kg/day and
oral vildagliptin 30 mg/kg/day, n = 20), and vehicle + vilda-
gliptin group (subcutaneous pH 4.0 HCl in saline and oral
vildagliptin 30 mg/kg/day, n = 20). Vildagliptin was ad-
ministered by gavage in 0.5% carboxymethyl cellulose
sodium. All animal protocols were approved and con-
ducted according to the recommendations of the Okayama
University Animal Care and Use Committee.
Oral glucose tolerance test
After rats were fasted for 18 h, glucose was orally adminis-
tered (2 g/kg). Blood samples were obtained before and
30, 60, 90, and 120 min after glucose loading. Bloodglucose concentrations were measured immediately
with a blood glucose monitor (Accu-Check, Roche), and
data were quantified by calculating the area under the
curve (AUC 0–120 min) using the trapezoidal rule.
Measurements of plasma active GLP-1, brain natriuretic
peptide, and pentosidine
Active (uncleaved, 7–36 amide or 7–37) GLP-1 was de-
tected using the commercially available enzyme-linked
immunosorbent assay kit (Millipore) using mouse in-
sulin standards; each sample was analyzed in duplicate.
This antibody only detects active GLP-1 (7–36 amide
or 7–37 GLP-1) but not cleaved GLP- 1 (9–36 amide
or 9–37 GLP-1). Plasma brain natriuretic peptide and
pentosidine were measured using an enzyme-linked
immunosorbent assay method at SRL Company Ltd.
(Tokyo, Japan).
DPP4 activity measurements
DPP4 activity was determined by the cleavage rate of 7-
amino-4-methylcoumarin (AMC) from the synthetic
substrate H-glycyl-prolyl-AMC (Gly-Pro-AMC; Sigma).
Briefly, 5 μl of sample was mixed with 35 μl of assay buf-
fer (25 mM HEPES). After 5-min preincubation at room
temperature, the reaction was initiated by the addition
of 40 μl of assay buffer containing 0.1 mM substrate
Gly-Pro-AMC. After incubation for 20 min, fluorescence
was determined using a spectrofluorometer (excitation
380 nm/emission 460 nm). The standard curve of free
AMC was generated using 0–50 mM AMC (Sigma).
DPP4 activity in plasma was expressed as the amount of
cleaved AMC per minute per ml (nmol/min/ml).
Echocardiography
Seven days after infusion, transthoracic echocardiography
was performed using a 10-MHz phased array transducer
(Aplio ver. 6.0, Toshiba, Japan) under 2% isoflurane. An
electrocardiogram was acquired simultaneously. End dia-
stole was defined as the peak of the R wave, and end sys-
tole was defined as the end of the T wave. All animals
underwent echocardiographic interrogation while lying in
a left recumbent position. Parasternal short-axis and
apical long-axis views were obtained. M-mode echocardi-
ography was performed using a parasternal short-axis view
at the level of the papillary muscles. LV posterior and
interventricular septal diastolic wall thicknesses (PWT
and IVST) were measured during diastole (d) and sys-
tole (s) as were the LV internal diameters at end dia-
stole (LVDd) and end systole (LVDs). Fractional
shortening (FS) was then calculated according to the
formula FS = [(LVDd− LVDs)/LVDd] × 100. LV mass (LVM)
was calculated according to 1.04 × [(LVDd + PWT +
IVST)3 – (LVDd) 3] [20] and LV mass index (LVMI) was
calculated by normalizing LVM for body weight. The
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transmitral peak diastolic flow velocities (E and A waves,
respectively).
Hemodynamic measurements
Seven days after infusion, rats were anesthetized, and a
micro-tip pressure transducer (Millar Instruments Inc.,
Houston, TX, USA) was inserted into the right carotid
artery. Arterial systolic and diastolic blood pressures
were recorded in the aortic arch. The catheter was
advanced into the LV cavity. After a 5-min period of
stabilization, heart rate, LV systolic pressure (LVSP), LV
end-diastolic pressure (LVEDP), and developed LV pres-
sure (dLVP = LVSP − LVEDP) were measured. For indi-
ces of contractility and relaxation, the maximal rates of
increase and decrease in LVP dp/dt maximum and dp/dt
minimum were determined.
Histology
The LV was fixed with 4% paraformaldehyde in phos-
phate buffered saline (PBS), embedded in paraffin, and
cut into 5-μm-thick sections. Sections were stained with
hematoxylin and eosin for morphological analysis and
with Masson’s trichrome to detect fibrosis and then ex-
amined by light microscopy. In sections stained with
Masson’s trichrome, interstitial fibrosis was measured
using computer-assisted image analysis, and the percent
fibrosis was calculated [21,22]. The widths of 30 individ-
ual cardiomyocytes in each group were measured as pre-
viously described. To visualize the capillaries in the
myocardium, endothelial cells in frozen sections were
stained with anti-rat CD31 Ab (BD Pharmingen) at
1:100 dilution. The antibody was visualized with a horse-
radish peroxidase (HRP)-conjugated goat anti-rat IgG
and streptavidin-HRP complex (Vectastain ABC elite kit,
Vector). HRP activity was detected with 0.025% dia-
minobenzidine and 0.03% H2O2 in PBS. Images were
captured with a light microscope, and capillaries were
evaluated as the number of vessels per cardiomyocyte.
Quantitative PCR
Total RNA was extracted from heart tissue using Trizol
(Invitrogen, Carlsbad, CA, USA). Total RNA (2 μg) was
reverse-transcribed using ReverTra Ace (TOYOBO, Osaka,
Japan). Finally, the cDNAs were diluted 5-fold before
conventional reverse transcription-PCR (RT-PCR) amp-
lification or 50-fold before quantitative PCR analysis.
Quantitative real-time RT-PCR was performed using a
LightCycler rapid thermal cycler system (Roche Applied
Science) as reported [23]. The PCR primers were as fol-
lows (forward primer and reverse primer): tumor necrosis
factor-alpha (Tnfa), 5′-TGAACTTCGGGGTGATCG-3′
and 5′- GGGCTTGTCACTCGAGTTTT-3′; interleukin-
6 (Il6), 5′-GCCCTTCAGGAACAGCTATG-3′ and 5′-GCAGTGGCTGTCAACAACA-3′; α-myosin heavy chain
(Myh6), 5′-CATGCGCATTGAGTTCAAGA-3′ and 5′-
TCATCCACGGCCAATTCT-3′; glucose transporter type
4 (Glut4), 5′-TTGCAGTGCCTGAGTCTTCTT-3′ and
5′-CCAGTCACTCGCTGCTGA-3′; insulin-like growth
factor-l (Igf1), 5′-ATGCCCAAGACTCAGAAGGA-3′ and
5′-CGTGGCATTTTCTGTTCCTC-3′; dipeptidylpepti-
dase 4 (Dpp4), 5′-CTCCAGAGGACAACCTTGAC-3′
and 5′-GGACAAGTGTGCTCTTGAGT-3′; glyceraldehyde
3-phosphate dehydrogenase (Gapdh), 5′-GGCAAGTTCA
ATGGCACAGT-3′ and 5′-TGGTGAAGACGCCAGTAG
ACTC-3′. Gapdh served as an internal control. Data were
analyzed using the standard curve method.Statistical analysis
All data are expressed as the mean ± SE. The two-tailed
Student’s t-test for two groups and one-way analysis of
variance followed by Tukey post-hoc test for more than
two groups were used. p-values < 0.05 were considered
significant.Results
Oral glucose tolerance test and active GLP-1 levels
Oral glucose tolerance and plasma GLP-1 levels in the
vehicle, ISO, vehicle-VL, or ISO-VL groups are shown in
Figure 1. The glucose levels at 120 minutes after glucose
loading were significantly lower in the ISO-VL and
vehicle-VL groups than in the vehicle and ISO groups
(Figure 1A). AUCs were also significantly smaller in the
ISO-VL and vehicle-VL groups than in the vehicle and
ISO groups (ISO-VL, 244 ±7 mg; vehicle-VL 243 ±
6 mg min/dl; vehicle, 264 ± 7 mg min/dl: ISO, 265 ±
8 mg min/dl, p < 0.05). Active GLP-1 levels at the fasting
state were significantly higher in the ISO-VL and vehicle-
VL groups than in the vehicle and ISO groups (Figure 1B),
and DPP4 activity at the fasting state was significantly
lower in the ISO-VL and vehicle-VL groups than in the
vehicle and ISO groups (Figure 1C).Body and heart weight
Body weight, heart weight, and the heart-to-body weight
ratio after 7 days of treatment are shown in Table 1. We
observed no difference in body weight among the four
groups at baseline or at 7 days post-treatment with ve-
hicle, ISO, vehicle-VL, or ISO-VL. The increases in
heart weight and heart-to-body weight ratio observed
for the ISO group were significantly suppressed in the
ISO-VL group (p < 0.05). Vildagliptin alone did not
affect heart weight or heart-to-body weight ratio. There-
fore, histological, hemodynamic and gene expression
analyses were performed only in rats treated with ve-
hicle, ISO, or ISO-VL.
Figure 1 Effects of vildagliptin on glucose tolerance, active GLP-1 levels, and DPP4 activity in isoproterenol-treated rats. Plots of blood
glucose over time (A), levels of active plasma glucagon-like peptide (GLP)-1 (B), and dipeptidyl peptidase (DPP)-4 activity (C) in vehicle, ISO,
ISO-VL, and vehicle-VL groups. Data represent the mean ± SE of 10 rats. *p < 0.05 vs. the vehicle and ISO groups.
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Hematoxylin and eosin staining after 7 days of treatment
revealed that the increase in cardiomyocyte width in the
ISO group was significantly suppressed in the ISO-VL
group (cardiomyocyte width: vehicle, 10.4 ± 0.2 μm; ISO,
13.4 ± 0.4 μm; ISO-VL, 11.1 ± 0.2 μm; Figure 2). Masson’s
trichrome staining revealed that the area of perivascular
fibrosis was significantly suppressed in the ISO-VL
group compared with the ISO group (area of fibrosis:
vehicle, 4.1 ± 1.8%; ISO, 7.4.5 ± 1.8%; ISO-VL, 5.8 ± 1.6%;
Figure 3A), but vildagliptin did not limit the increased area
of interstitial fibrosis caused by isoproterenol (area of fibro-
sis: vehicle, 0.72 ± 0.1%; ISO, 0.98 ± 0.2%; ISO-VL, 0.90 ±
0.1%; Figure 3B). CD31 staining revealed that the number
of CD31-positive capillaries/cardiomyocyte did not differ
among the three groups (vessels/cardiomyocyte: vehicle,
1.2 ± 0.1%; ISO, 1.1 ± 0.1%; ISO-VL, 1.2 ± 0.1%; Figure 4).Table 1 Effects of vildagliptin on heart weight
Vehicle
Number of rats 10
Body weight, g 237 ± 7
Heart weight, g 0.76 ± 0.10
Heart weight/body weight × 103 3.21 ± 0.40
ISO, isoproterenol; VL, vildagliptin. Values represent the mean ± SE. *p < 0.05 vs. veLV Hemodynamic and echocardiographic data
In non-invasive tail-cuff blood pressure measurements,
systolic blood pressure at day 7 was significantly higher
in the ISO-VL group than in the vehicle and ISO
groups (127 ± 6, 119 ± 5, and 117 ± 5 mmHg, respectively,
p < 0.05); however, cardiac catheterization showed no dif-
ferences in systolic pressure among the three groups.
As shown in Table 2, hemodynamic data by cardiac
catheterization revealed diastolic dysfunction in ISO-
treated rats. ISO-treated rats showed significantly
increased maximum dp/dt, depressed minimum dp/dt,
and elevated LVEDP compared with vehicle-treated
rats, but there was no significant difference in LVSP
between the three groups. Vildagliptin significantly im-
proved LVEDP in ISO-treated rats, whereas no signifi-
cant differences were found in maximum dp/dt or
minimum dp/dt between the ISO group and the ISO-ISO ISO-VL Vehicle-VL
20 20 20
235 ± 10 234 ± 11 237 ± 6
1.04 ± 0.11* 0.97 ± 0.10*# 0.75 ± 0.09
4.43 ± 039* 4.14 ± 0.29*# 3.16 ± 0.16
hicle and vehicle-VL; #p < 0.05 vs. ISO.
Figure 2 Effect of vildagliptin on cardiomyocyte size in isoproterenol-treated rats. Hematoxylin and eosin staining of hearts in the vehicle,
ISO, and ISO-VL treatment groups. The widths of 30 individual cardiomyocytes in rat were measured across a line bisecting the nucleus.
Scale bar = 100 μm. Bar graph shows the cardiomyocyte width. Values represent the mean ± SE. n = 6 each. NS = not significant.
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LV systolic function among the three groups, and vil-
dagliptin attenuated the increase in LVM and LVMI in
ISO-treated hearts (Table 2).
Cardiac gene expression
Figure 5 shows levels of mRNA expression in the heart
after treatment. The increased expression of genes that
encode inflammatory markers such as Tnfa and Il6 upon
ISO treatment was significantly suppressed by vildagliptin
(Figure 5A and B). Expression of the gene that encodes
Myh6, which is the dominant major histocompatibility
complex (MHC) isoform expressed in normal hearts, was
significantly decreased in the ISO group (Figure 5C). Vil-
dagliptin significantly limited the decrease in expression of
Myh6 mRNA. The mRNA expression of the gene that en-
codes Glut4, which mediates glucose uptake, was signifi-
cantly reduced by isoproterenol treatment. Vildagliptin
also significantly limited the decrease in Glut4 mRNA
(Figure 5D). The increased expression of Igf1 mRNA upon
isoproterenol treatment was significantly suppressed by
vildagliptin (Figure 5E). The expression of Dpp4 mRNA
was not affected by isoproterenol treatment (Figure 5F).
Measurements of brain natriuretic peptide and pentosidine
After 7 days of treatment, the increase in brain natriuretic
peptide (BNP) level in the ISO group was significantly
suppressed in the ISO-VL group (vehicle, 52.2 ± 2.3 pg/ml;
ISO, 74.7 ± 6.9 pg/ml; ISO-VL, 62.0 ± 2.3 pg/ml, p < 0.05).There was no difference in the plasma levels of pentosidine,
which is an advanced glycation end product and is gener-
ated by non-enzymatic glycation and oxidation of proteins
(vehicle, 9.4 ± 0.51 μg/ml; ISO, 8.8 ± 0.63 μg/ml; ISO-VL,
9.4 ± 0.52 μg/ml).
Discussion
We demonstrated that short-term treatment with a
DPP4 inhibitor, vildagliptin, prevented LV hypertrophy
caused by continuous infusion of isoproterenol. These
effects were accompanied by the amelioration of expres-
sion of genes associated with glucose uptake and inflam-
mation. Although cardiac catheterization showed that
vildagliptin did not significantly improve LV diastolic
dysfunction in isoproterenol-treated rats, this study indi-
cated that vildagliptin has potential for preventing LV
hypertrophy independent of blood pressure.
Regarding the mechanisms underlying the protective
effect of vildagliptin in preventing isoproterenol-induced
LV hypertrophy in this study, one possible explanation is
that vildagliptin may reduce inflammation in the heart. A
previous study showed that isoproterenol induces expres-
sion of mRNAs that encode myocardial pro-inflammatory
cytokines such as TNF-α, IL-6, and IL-1β [24]. Our previ-
ous study revealed a direct effect of TNF-α on cardiac
hypertrophy in cultured cardiomyocytes [25]. Thus, TNF-α
and IL-6 are likely to be important factors in the induction
of hypertrophy [26,27]. In our current study, vildaglip-
tin reduced the expression of Tnfa and Il6 mRNAs in
Figure 3 Effect of vildagliptin on cardiac fibrosis in isoproterenol-treated rats. Masson’s trichrome staining of hearts in the vehicle, ISO, and
ISO-VL treatment groups. A: Perivascular fibrosis. B: Interstitial fibrosis. Scale bars = 100 μm. Bar graphs show the area of fibrosis (%) in each case.
Values represent the mean ± SE. n = 6 each. NS, not significant.
Miyoshi et al. Cardiovascular Diabetology 2014, 13:43 Page 6 of 10
http://www.cardiab.com/content/13/1/43myocardial tissue of isoproterenol-treated rats. Similarly,
recent studies demonstrated the effect of DPP4 inhibitors
on the reduction of pro-inflammatory cytokines in macro-
phages, visceral adipose tissue, and atherosclerotic plaques
[28,29]. Furthermore, vildagliptin suppressed the increase
in Igf1 expression induced by isoproterenol in our rat
model. Recent studies showed the involvement of IGF1 in
cardiomyocyte hypertrophy [30,31]. Thus, a change in
cytokine expression by vildagliptin may contribute to the
prevention of LV hypertrophy. Another possibility is that
increased active GLP-1 levels by vildagliptin directlyinfluences LV hypertrophy. In several previous experi-
ments in rats, oral vildagliptin was used at a dose of 3 to
60 mg/kg/day [11,32]. We selected the dose of 30 mg/kg/
day of vildagliptin in this study and confirmed that this
dosage increased the GLP-1 level at the fasting state by
2-fold compared with the control group. A study showed
that recombinant GLP-1 infusion for 14 days reduces blood
pressure, LV hypertrophy, and LV fibrosis in Dahl salt-
sensitive rats [33]. Another group has reported that ad-
ministration of a GLP-1 analog diminishes cardiac
hypertrophy and blood pressure in obese mice exhibiting
Figure 4 Effect of vildagliptin on capillary vessels in isoproterenol-treated rat myocardium. CD31 staining of hearts in the vehicle, ISO, and
ISO-VL groups. Scale bar = 100 μm. Bar graph shows the number of vessels per cardiomyocyte. Values represent the mean ± SE. n = 6 each. NS,
not significant.
Table 2 Effects of vildagliptin on LV hemodynamic and echocardiographic data
Vehicle ISO ISO-VL
Cardiac catheterization
Number of rats 10 10 10
Heart rate (bpm) 404 ± 8 519 ± 7* 491 ± 8* #
LVSP (mmHg) 108 ± 3 113 ± 2 116 ± 2
LVEDP (mmHg) 2.2 ± 1.1 3.4 ± 0.9* 2.5 ± 1.0#
Maximum dp/dt (mmHg/s) 8992 ± 434 16,969 ± 592* 16,189 ± 713*
Minimum dp/dt (mmHg/s) −8251 ± 531 −9936 ± 459* −10080 ± 236*
Echocardiography
Number of rats 10 10 10
LVDd (mm) 6.78 ± 0.14 6.71 ± 0.04 6.74 ± 0.08
LVDs (mm) 3.62 ± 0.14 3.29 ± 0.08 3.41 ± 0.07
FS (%) 46.7 ± 2.7 51.0 ± 1.1 50.0 ± 0.9
IVST (mm) 1.34 ± 0.04 1.57 ± 0.23* 1.51 ± 0.03*
PWT (mm) 1.38 ± 0.04 1.62 ± 0.03* 1.56 ± 0.03*
E/A 1.61 ± 0.24 1.57 ± 0.07 1.53 ± 0.05
LVM (mg) 567 ± 16 695 ± 9* 663 ± 11* #
LVMI (mg/g) 2.36 ± 0.06 2.96 ± 0.04* 2.83 ± 0.04* #
ISO, isoproterenol; VL, vildagliptin; LVSP, left ventricular systolic pressure; LVEDP, left ventricular end diastolic pressure; LVDd, left ventricular end-diastolic diameter;
LVDs, left ventricular end-systolic diameter; FS, fractional shortening; IVST, interventricular septal thickness; PWT, posterior wall thickness; E, early transmitral peak
diastolic flow velocity; A, late transmitral peak diastolic flow velocity; LVM, left ventricular mass; LVMI, left ventricular mass index. Values represent the mean ± SE.
*p < 0.05 vs. vehicle; #p < 0.05 vs. ISO.
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Figure 5 Cardiac gene expression in isoproterenol-treated rats. The changes in expression of tumor necrosis factor alpha (Tnfa) (A),
interleukin-6 (Il6) (B), α-myosin heavy chain (Myh6) (C), glucose transporter type 4 (Glut4) (D), insulin-like growth factor (Igf1) (E), and dipeptidyl
peptidase-4 (Dpp4) (F) mRNAs were analyzed using quantitative PCR. Values represent the mean ± SE. n = 8 each. NS, not significant.
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to discriminate the effect of GLP-1 on the protection
of LV hypertrophy from its blood pressure–lowering
effects. Taken together, these results suggest that the
anti-inflammatory effect and suppression of IGF1 by
vildagliptin in the heart at least partly counters LV
hypertrophy.
In this study, although LVEDP was significantly lower in
the ISO-VL group than in the ISO group, other catheter-
related parameters such as maximum dp/dt, minimum
dp/dt were similar between the two groups. Thus, this
study failed to demonstrate that vildagliptin ameliorated
LV diastolic function in the ISO-VL group. Energy metab-
olism, however, switches from fatty acid oxidation to
carbohydrate oxidation in hypertrophied hearts [35], and
thus the increase in expression of Glut4 mRNA by vilda-
gliptin may improve glucose uptake in cardiomyocytes
and then ameliorate ATP synthesis through carbohydrate
oxidation. In fact, treatment with a DPP4 inhibitor, sita-
gliptin, improves insulin resistance and increases cardiac
GLUT4 protein and mRNA abundance in spontaneously
hypertensive rats [36]. In hypertrophied hearts, the shift in
MHC isoform composition from α- to β-MHC has also
been reported [37]. Our finding that expression of cardiac
α-MHC (Myh6) mRNA decreased in isoproterenol-treated
rats is consistent with those previous data. The improve-
ments in energy production have beneficial effects on fail-
ing hearts and may upregulate Myh6 expression. In thisstudy, although insulin sensitivity was not assessed, rats in
the ISO and vehicle groups exhibited similar glucose toler-
ance patterns. Given that vildagliptin lowered the AUCs in
both isoproterenol-treated and vehicle-treated rats, vilda-
gliptin may exert favorable effects on insulin signaling in
isoproterenol-treated hearts. This study also demonstrated
that decreased inflammatory cytokines may contribute to
dysregulated cardiac signaling. Other studies have shown
that TNF-α causes cardiac insulin resistance by inducing
degradation of insulin receptor substrate protein 1, which
is critical for cardiac insulin signaling [38,39]. Thus, re-
duced expression of Tnfa mRNA by vildagliptin, as shown
in our present study, also partly contributes to the increase
in energy production in isoproterenol-treated hearts. On
the other hand, histological analyses in this study showed
that vildagliptin significantly suppressed perivascular fi-
brosis in isoproterenol-treated hearts but did not affect
angiogenesis. One study showed that vildagliptin reverses
angiogenesis in diabetic murine hearts by increasing the
activity of stromal cell–derived factor-1α, which is a sub-
strate of DPP4 [40]. The lack of change in angiogenesis in
the isoproterenol-infused rat model may explain why dia-
stolic function is not significantly improved.
DPP4 is widely expressed on the surface of endothelial
cells and immune cells such as lymphocytes and mono-
cytes [40-42]. DPP4 inhibitors exert their effects by inhi-
biting enzymatic degradation of GLP-1; however, recent
studies reported non-enzymatic functions for DPP4 [43].
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responses in innate immune cells such as monocytes and
dendritic cells through the incretin-independent pathway
[44,45]. In endothelial cells, DPP4-mediated signaling path-
ways result in phosphorylation of endothelial nitric oxide
synthase [41]. The distinct role of DPP4 in cardiac tissue
remains unknown, but further examination will shed light
on the novel functions of DPP4 inhibitors in the heart.
Although the effects of DPP4 inhibitors on LV hyper-
trophy in humans have not been fully elucidated, the mod-
erate blood pressure–lowering effect of DPP4 inhibitor may
have favorable effect on LV hypertrophy in this clinical set-
ting [46]. The mechanism of this effect has been attributed
to increased diuresis and natriuresis owing to inhibition of
sodium reabsorption from the proximal renal tubules [47].
Another mechanism for the blood pressure–lowering ef-
fects of DPP4 inhibitors is peripheral vasodilatation and de-
creased peripheral vascular resistance. Recently, van Poppel
et al. showed that vildagliptin improves endothelial function
in patients with type 2 diabetes [48]. Moreover, a recent
clinical study indicated that endothelial dysfunction is
closely associated with HFpEF [49], and thus favorable
effects of DPP4 inhibitors on the vascular system suggest a
therapeutic potential for preventing LV hypertrophy and
HFpEF in humans.
Limitations
The elevation of the circulating GLP-1 level has a potential
role in cardioprotection, but we did not explore the direct
effect of GLP-1 on hypertrophy of cardiomyocytes in this
study. Further, a wide range of peptides are considered to
be substrates of DPP4. Comprehensive analysis of the effect
of DPP4 inhibitors on the substrates in hypertrophied
hearts will help to identify the underlying mechanisms.
Second, our finding indicated the potential role of vildaglip-
tin on the protection, but not regression, of LV hyper-
trophy. In clinical practice, it would be of interest to see if
administration of DPP4 inhibitor has benefits for patients
with existing LV hypertrophy. Further study is warranted to
address this question. Finally, It is necessary to understand
the role of DPP4 itself in cardiac hypertrophy to address
the potential role of DPP4 inhibitors as therapeutics.
In conclusion, a DPP4 inhibitor, vildagliptin, prevented LV
hypertrophy caused by continuous exposure to isoproterenol
in rats. This finding suggests the possibility of using a DPP4
inhibitor to prevent LV hypertrophy in humans.
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